Endo International plc Provides Financial Guidance for the Second Quarter of 2020
Endo International plc provided financial guidance for the second quarter of 2020. The company expects total revenues to decline in the low 20% range in the second quarter compared to the first quarter of 2020. This decline primarily reflects an expected decline in Branded Pharmaceuticals revenue in the low to mid-60% range compared to the first quarter driven by a reduction in physician-administered products included in the Specialty Products portfolio, resulting from office closures and a decline in patients electing to be treated.